Hemodynamic responses to a hemoglobin bis‐tetramer and its polyethylene glycol conjugate
- 9 November 2011
- journal article
- Published by Wiley in Transfusion
- Vol. 52 (5), 974-982
- https://doi.org/10.1111/j.1537-2995.2011.03421.x
Abstract
BACKGROUND: The design of hemoglobin-based oxygen carriers (HBOCs) poses a significant challenge as clinical trials of many materials have reported adverse side effects that may come from the scavenging of the vasodilator nitric oxide (NO). A compensating reaction, reduction of endogenous nitrite by hemoglobin (Hb) and its derivatives, generates NO. Polyethylene glycol (PEG) conjugation of Hb enhances the rate of the reaction. STUDY DESIGN AND METHODS: Hemoglobin bis-tetramers (BT) and their PEGylated derivative (BT-PEG) bind oxygen with a degree of cooperativity and also have significantly enhanced nitrite reductase activity compared to the native protein. Circulatory evaluation will test if the properties of BT and BT-PEG are reflected in their effects in vivo. BT and BT-PEG were evaluated as infusions into healthy wild-type (WT) and diabetic (db/db) mouse models. The effects were compared to infusions of murine Hb. RESULTS: The materials were found not to cause significant increases in systemic blood pressure in either WT mice or db/db mice. The latter are highly sensitive to NO scavenging. Further hemodynamic measurements in WT mice indicate that while a slight increase in systemic vascular resistance (SVR) was observed after infusion of BT, the extent is not significant. No change in SVR from baseline was observed after infusion of BT-PEG. CONCLUSION: The enlarged Hb derivatives do not evoke unfavorable circulatory responses that have been noted to result from infusion of Hb derivatives. These results suggest that a compromise between the P50, n50, and nitrite reductase activity of a Hb derivative can serve as the basis for producing HBOCs that can be tested for vasoactivity.Keywords
This publication has 30 references indexed in Scilit:
- Red cell substitutes from hemoglobin—Do we start all over again?Current Opinion in Chemical Biology, 2010
- Hemoglobin-based oxygen carriers: from mechanisms of toxicity and clearance to rational drug designTrends in Molecular Medicine, 2010
- Hemoglobin‐based oxygen carriers: current status and future directionsTransfusion, 2009
- Will fixing the vasoactivity caused by hemoglobin-based oxygen carriers be enough?*Critical Care Medicine, 2009
- Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and DeathJAMA, 2008
- Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Unraveling the Reactions of Nitric Oxide, Nitrite, and Hemoglobin in Physiology and TherapeuticsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- MP4, a new nonvasoactive PEG‐Hb conjugateTransfusion, 2003
- Nitric oxide NO - biogeneration regulation and relevence to human diseasesFrontiers in Bioscience-Landmark, 2003
- A Short History Of Nitroglycerine And Nitric Oxide In Pharmacology And PhysiologyClinical and Experimental Pharmacology and Physiology, 2000